Reform and Prospect of Systemic Therapy on HER2-positive Early-stage Breast Cancer
In the past two decades, the survival of HER2-positive early-stage breast cancer patients has significantly improved with the development of HER2-targeted therapies. The focus has been placed on maximizing the clinical benefit of HER2-positive early-stage breast cancer by optimizing the treatment fr...
Main Authors: | LIU Guangyu, WU Siyu |
---|---|
Format: | Article |
Language: | zho |
Published: |
Magazine House of Cancer Research on Prevention and Treatment
2023-05-01
|
Series: | Zhongliu Fangzhi Yanjiu |
Subjects: | |
Online Access: | http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2023.22.1521 |
Similar Items
-
HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future
by: Luying Xu, et al.
Published: (2024-09-01) -
A Multi-Centre Randomized Study Comparing Two Standard of Care Chemotherapy Regimens for Lower-Risk HER2-Positive Breast Cancer
by: Ricardo Fernandes, et al.
Published: (2023-08-01) -
Management of HER2-Positive Early Breast Cancer in Italy: A Maze Presenting Opportunities and Challenges
by: Luigia Stefania Stucci, et al.
Published: (2022-05-01) -
Analysis of clinicopathological characteristics and prognostic factors of early‐stage human epidermal growth factor receptor 2 (HER2)‐low breast cancer: Compared with HER2‐0 breast cancer
by: Qian Wu, et al.
Published: (2023-10-01) -
Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer
by: Arlene Chan, et al.
Published: (2023-02-01)